List view / Grid view
Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.
8 January 2013 | By FOSS NIRSystems Inc
FOSS NIRSystems, Inc. announce that a new FOSS NIR article has been published...
7 January 2013 | By Gilead Sciences
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Sirius Analytical Instruments Ltd
“We are delighted to begin this strategic partnership with Paraytec..."
7 January 2013 | By Gerresheimer
Gerresheimer is exhibiting at Pharmapack 2013, 13-14 February, stands 133 and 372...
7 January 2013 | By Sanofi
“I am delighted that Dr. Gary Nabel will continue to make this Council a vital part of our efforts..."
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
7 January 2013 | By Merck
“We are pleased the FDA has accepted our resubmission of sugammadex sodium injection for review..."
4 January 2013 | By BUCHI Labortechnik AG
BÜCHI Labortechnik AG expands its worldwide presence with the opening of the new Moscow office...
4 January 2013 | By Biogen Idec
Half-life of long-lasting rFIXFc may enable prophylactic dosing every 1-2 weeks...
3 January 2013 | By Biogen Idec
EMPOWER trial fails to demonstrate efficacy in primary and key secondary endpoints...
3 January 2013 | By EMD Serono; Pfizer Inc.
The majority of patients found Rebif Rebidose easy to use in a user trial...
3 January 2013 | By Abbott
FDA approval - XIENCE Xpedition™ Everolimus Eluting Coronary Stent System...
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
